U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H16F2N8O2
Molecular Weight 426.3795
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VERICIGUAT

SMILES

COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=CC=CC=C3F)C4=NC=C(F)C=C24

InChI

InChIKey=QZFHIXARHDBPBY-UHFFFAOYSA-N
InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)

HIDE SMILES / InChI
Molecular Formula C19H16F2N8O2
Molecular Weight 426.3795
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Vericiguat, discovered at Bayer, is the first soluble guanylate cyclase (sGC) stimulator. Vericiguat is currently being studied in a Phase III clinical program for the treatment of heart failure with reduced ejection fraction (HFrEF).

Originator

Approval Year

2021
478
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1404
 1005.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
651
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
2017 Jun 22
Patents

Patents

08420656
2
20120022084
2
20130143900
2

Sample Use Guides

In Vivo Use Guide
Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.
Route of Administration: Oral
In Vitro Use Guide
Studies on the in vitro effects of Vericiguat on highly purified sGC (soluble guanylate cyclase) revealed that Vericiguat (0.01 uM to 100 uM) stimulates recombinant sGC concentration dependently, by 1.7-fold to 57.6-fold.
Substance Class Chemical
Created
by admin
on Sat Dec 17 21:39:16 UTC 2022
Edited
by admin
on Sat Dec 17 21:39:16 UTC 2022
Record UNII
LV66ADM269
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VERICIGUAT
INN  
USAN   INN  
Official Name English
METHYL N-(4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)PYRIMIDIN-5-YL)CARBAMATE
Systematic Name English
vericiguat [INN]
Common Name English
METHYL (4,6-DIAMINO-2-(5-FLUORO-1-((2-FLUOROPHENYL)METHYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL(PYRIMIDIN-5-YL)CARBAMATE
Systematic Name English
METHYL (4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)PYRIMIDIN-5-YL)CARBAMATE
Systematic Name English
BAY-1021189
Code English
VERICIGUAT [JAN]
Common Name English
VERICIGUAT [ORANGE BOOK]
Common Name English
VERQUVO
Brand Name English
Vericiguat [WHO-DD]
Common Name English
MK-1242
Code English
VERICIGUAT [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29707
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
Code System Code Type Description
FDA UNII
LV66ADM269
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
WIKIPEDIA
Vericiguat
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
CHEBI
142432
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
INN
9805
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
DRUG BANK
DB15456
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
DAILYMED
LV66ADM269
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
NCI_THESAURUS
C152862
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
CAS
1350653-20-1
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
PUBCHEM
54674461
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
RXCUI
2475830
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
USAN
GH-146
Created by admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
PRIMARY
Related Record Type Details
Structure of VERICIGUAT HYDROCHLORIDE
SALT/SOLVATE -> PARENT
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Protein binding (primarily to serum albumin) of vericiguat is about 98%.
BINDING
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A9
METABOLIC ENZYME -> SUBSTRATE
GUANYLATE CYCLASE SOLUBLE .ALPHA.1.BETA.1
TARGET -> ACTIVATOR
Related Record Type Details
Structure of VERICIGUAT
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Structure of VERICIGUAT
IN HEALTHY SUBJECTS
PHARMACOKINETIC
Tmax PHARMACOKINETIC
Structure of VERICIGUAT
FASTED STATE
PHARMACOKINETIC
ABSOLUTE BIOAVAILABILITY PHARMACOKINETIC
Structure of VERICIGUAT
FED CONDITION
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Structure of VERICIGUAT
IN PATIENTS WITH HEART FAILURE
NUCLEIC ACID FEATURE
Tmax PHARMACOKINETIC
Structure of VERICIGUAT
HIGH-FAT, HIGH-CALORIE MEAL
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966